S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
LON:ETX

e-therapeutics (ETX) Share Price, News & Analysis

GBX 11.30
+0.15 (+1.35%)
(As of 06:21 AM ET)
Today's Range
11.30
11.49
50-Day Range
11.30
18.13
52-Week Range
8
24
Volume
70,914 shs
Average Volume
343,955 shs
Market Capitalization
£66.03 million
P/E Ratio
N/A
Dividend Yield
3.35%
Price Target
N/A
ETX stock logo

About e-therapeutics Stock (LON:ETX)

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.

ETX Stock Price History

ETX Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
e-therapeutics appoints new CFO
ETX.L - e-Therapeutics plc
Elicio Therapeutics Inc.
8-K: Seres Therapeutics, Inc.
e-Therapeutics plc (ETX.L)
See More Headlines
Receive ETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/17/2020
Today
3/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
34
Year Founded
N/A

Profitability

Net Income
£-10,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£295,000.00
Cash Flow
GBX 2.20 per share
Book Value
GBX 5 per share

Miscellaneous

Free Float
N/A
Market Cap
£65.15 million
Optionable
Not Optionable
Beta
0.48
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Ahmad Ali Mortazavi (Age 53)
    CEO & Director
    Comp: $270k
  • Mr. Timothy Bretherton
    CFO, Director of Finance & Operations and Company Secretary
  • Dr. Laura Roca-Alonso Ph.D.
    Chief Operating Officer
  • Mr. Alan Whitmore B.Sc.
    Ph.D., Chief Scientific Officer
  • Mr. Ankit Sharma
    Head of Software Engineering
  • Mr. Graham Craggs
    Head of Therapeutic Discovery

ETX Stock Analysis - Frequently Asked Questions

How have ETX shares performed in 2024?

e-therapeutics' stock was trading at GBX 8.24 at the start of the year. Since then, ETX shares have increased by 37.1% and is now trading at GBX 11.30.
View the best growth stocks for 2024 here
.

How were e-therapeutics' earnings last quarter?

e-therapeutics plc (LON:ETX) released its quarterly earnings results on Tuesday, March, 17th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.03.

What other stocks do shareholders of e-therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4D pharma (DDDD), Chicken Soup for the Soul Entertainment (CSSE), Crescent Point Energy (CPG), Collagen Solutions plc (COS.L) (COS), BP (BP), Bushveld Minerals (BMN) and Alstom (ALSMY).

How do I buy shares of e-therapeutics?

Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ETX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners